Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | UNC79 | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-06 |
mRNA | TCERG1L | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-06 |
mRNA | ARID1B | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-06 |
mRNA | SEPT5 | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-06 |
mRNA | C20orf24 | CTRPv2 | pan-cancer | AAC | -0.16 | 1e-06 |
mRNA | DHPS | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-06 |
mRNA | PFDN4 | CTRPv2 | pan-cancer | AAC | -0.16 | 1e-06 |
mRNA | LRRC34 | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-06 |
mRNA | TUBA1A | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-06 |
mRNA | GP1BB | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-06 |